July 29, 2025 • 14 mins
AstraZeneca may sell some of its medicines directly to patients in the US, according to Chief Executive Officer Pascal Soriot. AstraZeneca is looking to the US for growth, with Soriot saying the company will be self-sufficient in the US in a couple of months. He speaks with Bloomberg's Carol Massar, Tim Stenovec, and Madison Muller
See omnystudio.com/listener for privacy information.
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:02):
Bloomberg Audio Studios, podcasts, radio news.
Speaker 2 (00:08):
Well, as you know, tariff talks continuing, as do presidential
statements about more manufacturing back here in the United States.
The pharmaceutical industry among the latest to be targeted by
President Trump, who made comments Monday from Scotland.
Speaker 3 (00:21):
We'll be announcing on pharmaceuticals sometime in the very near future.
We have a very big plan on pharmaceuticals. We want
to bring a lot of the pharmaceuticals back to America.
Will you know the way they should be. We're going
to want to be making a lot of them ourselves,
all of them in a sense. But you also have
a good pharmaceutical business. We'll be dealing with you on pharmaceuticals.
Speaker 2 (00:43):
All right. That, of course, was President Trump on Monday
from Scotland. We've got a great voice on this and
really the overall pharma industry. Big Pharma. A company that
reported earnings earlier today. We're talking about Astrazenica. Eighty hours
of the company, by the way, are rallying more than
four percent in today's session. Great to have with us
in studio. Pascal Sorio. He is Astrozenica's chief executive officer.
(01:03):
Also with us a member of our editorial team here
at Bloomberg knows this company and industry so well as
Bloomberg News health reporter Madison Muller. Pascal, by the way,
also a former CEO of Genentech. Thank you, thank you
for joining us.
Speaker 4 (01:15):
Welcome, thank you for having me. It's very a pleasure,
thank you.
Speaker 2 (01:18):
It's a pleasure for us. Big space, a space that's
certainly garnered the attention of President Trump. I am curious,
you know, in terms of the President talking about more
manufacturing in the United States, and I know you guys
are making some further investments here, talk to us about
how presidential policy is impacting maybe your business.
Speaker 5 (01:36):
Yeah, I mean, I think, first of all, it's a
great question. But first of all, it's important to really
think about what every country.
Speaker 4 (01:42):
Would want to do. Every country would want.
Speaker 5 (01:45):
To make sure they can and they can secure the
health of their citizens.
Speaker 4 (01:48):
It's a question of national security.
Speaker 5 (01:50):
So nobody should be surprised that the president wants to
reshore manufacturing or pharmaceutical products. I personally, I have seen
this happen since several years, and we decided several years
ago to increase some manufacturing footprint in the US. So
we can actually manufacture many scenes for American patients in America.
(02:11):
Every country would want to do that, and a big
country like America, of course, kind of thought to do it.
Speaker 1 (02:16):
You said that you made that decision several years ago.
How much of the fifty billion dollar pledge was planned
before the President threatened these terraffts.
Speaker 5 (02:24):
Well, we've been pursuing this strategy of manufacturing in China
for China, in the US for the US since five
six years and quite frankly, COVID actually showed us we
were on the right track because we all saw what
happened during COVID, and so we accelrated this movement and
sour fifty billion commitment is a commitment to R and
D but also commitment to manufacturing. We announced together with
(02:46):
the Governor of Virginia, a multi billion dollar investment in
manufacturing in Virginia, and the Governor of Virginia has been
incredibly fast with this team, thirty three days to reach
an agreement. It's incredible, so we're very happy to be there.
We are building a new R and D site in
Kendle Square, Cambridge, Massachusett, with twenty five hundred scientists that
we'll be working there, and there's more to come. We're
(03:08):
just finishing the build of a cels Rup manufacturing site
in Rockville, Maryland. We've expanded in California. So so it's
a sort of multi plane effort across many states across
the US.
Speaker 6 (03:23):
You know, you've said that Virginia obviously has made it
easy to make manufacturing investments there in North Carolina is
pretty similar. Are there other states in the US where
you're having these types of good conversations that are you know,
incentivizing businesses like yours to invest.
Speaker 5 (03:39):
Well, you know, it's hard for me to point the
point that any state that is better than another.
Speaker 4 (03:45):
Let me just say that we have.
Speaker 1 (03:47):
No problem from different in New Jersey.
Speaker 5 (03:55):
Let me let me just say that the company like
ours follow the science. So science is key, and so
you need to be able to recruit the right scientences,
the right engineers. And in Virginia you can do this
because you have some of the best university universities. The
other part is dealing with partners in a public sector
that understand us.
Speaker 4 (04:14):
That we trust each other, we can move fast.
Speaker 5 (04:16):
You know, I always tell people in our company talk
about as Tazenica speed, because there's a lot of competition.
We need to move fast. I've learned Virginia speed. The
governor has moved so quickly. So this is the kind
of thing we want to see, whether it's in America,
in a state or in a country. We want speed
and we want people who understand how we think.
Speaker 1 (04:36):
You want speed. You want people to understand how you
think you want to You said you want to follow
the science. There has been criticism that Robert F. Kennedy, Junior,
the Secretary of Health and Human Services, has not necessarily
always followed the science with his comments when it comes
to medicine, when it comes to drugs, when it comes
to vaccines. How do you look at that and his
role there.
Speaker 5 (04:54):
Well, you know, I'm not here to actually get involved
in political discourses. Let me just say that as a company,
science is at the heart of everything we do. The
reason we have such a large oncology pipeline in particular
and beyond this is because we've focused on science for
the last ten twelve years. And America is where science
(05:17):
in our industry is happening. And that's why it's so
critical to preserve this biosciences leadership. The US has globally
China is also becoming a very big source of innovation
in our industry. Your open fortunately is falling behind for
a variety of reasons. So innovation is happening here. We
need to keep this going.
Speaker 4 (05:36):
We need to.
Speaker 5 (05:36):
Actually continue supporting the leadership. And that's why we invest
fifty billion dollars in this country, not only in manufacturing
but also in R and D.
Speaker 2 (05:45):
What about China, I'd love you to kind of explore
that a little bit. What are you investing in and
building out in China and what might surprise our audience
about the innovation that's happening in China, especially when it
comes to pharmaceuticals.
Speaker 4 (05:58):
Yeah, I think my great question, and I think we
need to start.
Speaker 5 (06:01):
With the the hypothesis, the assumption that basically the more
products or the more innovation exists in the world, the
better it is for everybody, for every patient, because if
you have a patient with cancer, the only thing that
you care about is to be cured if you can
be cured, right, And so innovation in China has really
ramped up very rapidly in the last few years. China
(06:22):
has gone from making generics to me toos to Metwo
plus what we call meet two plus in our industry
to truly innovate these days, innovate in new technologies and
cell therapy in si RN, in many many technologies, and
so China has become the second engine of innovation, not
as big as the US. The US remains the leader
(06:45):
in that field, but China is ramping up very quickly.
Speaker 2 (06:48):
Is the administration with some of it, some would say
questionable disruptive policies. There's been a lot of reporting about
scientists kind of leaving the United States and going elsewhere.
Are you seeing signs of that, whether it's to Europe,
to China to elsewhere because of not supporting, you know,
academia and academic universities. Some of that seems to be
(07:09):
coming back.
Speaker 5 (07:09):
But yeah, but you know, in these things, it's always
difficult to discern what is anecdotal versus what is systemic.
What we have seen in China is really a substantial
return of scientists from the US but also from the
UK and elsewhere, but not because of policy, simply because
they could see opportunities in China. There is money, there
(07:30):
is capital that can be invested. The Chinese are willing
to take rise. The government has facilitated the return of
the scientists, and they've come back. But I can tell
you that a lot of the scientists we work with
and China in about the companies that we partner with,
many of these people are American, the American Chinese. I
mean they go back and forth, back and forth. There
are bridged between the US and China. But they've gone
(07:54):
to China because of the opportunities to create a company,
be funded, tach risk and and.
Speaker 4 (08:00):
Hopefully be successful and buy and large. They've been quite successful.
Speaker 5 (08:05):
I want to say though, that the leadership remains with
the US and we need to maintain this, of course,
I mean the country needs to maintain this.
Speaker 6 (08:14):
There's been some concern though that companies like yours, you know,
not necessarily astro, but big pharmaceutical companies are going to
China for most of their biotech deals. Now, you know,
what would you say to that and what would US
biotech companies need to do to sort of attract investments
from from well, I.
Speaker 5 (08:32):
Mean the first thing I would say is that if
you're a patient, you don't care. What you want is
a drug that will help you. Right, So when we
do a deal with a Chinese company, typically it's because
they've discovered a product and they need help to globalize it.
Because discovering something in a lab is one thing. It
(08:52):
doesn't require a huge amount of money. It require us
very talented people, but the capital requirement is limited. When
you want to develop globally, then you need to scale.
You need billions of dollars of investment in phase two,
phase three, and you need to scale. You need the people,
the expertise. So what we do is we lice on
sindle product and then we develop them globally and then
(09:12):
bring them to patients so they start the innovation started
in China but becomes a global medicine for everybody, so
it really benefits everybody around the world.
Speaker 1 (09:24):
I want to go back to sort of a global
domestic question the idea of your listing, and the Times
of London has said that Astro Zeneka is looking to move.
It's listening to the US.
Speaker 4 (09:35):
Are you going to do that?
Speaker 2 (09:36):
Well, you just shirt with us.
Speaker 3 (09:39):
Yeah.
Speaker 5 (09:40):
We don't comment on rumors, and you know, as a
company over the last ten years we've had so many rumors.
We don't comment on rumors. The only thing I will
say really is the United States is really core to
our company. By two thousand and thirty, we expect fifty
percent of our revenue to come out of the United States.
Today it's forty four forty five percent. We're all tremendously
(10:02):
in the US, and the first half. The US is
the country that innovates, I just audio, but also the
countries that uptake the innovation faster, patients benefit much faster.
So we want to invest here and we want to
grow here, and that is a very critical part of
our company globally.
Speaker 2 (10:22):
Just curious in terms of growth. You know, we've talked
about earnings and your cancer drugs are certainly important in
terms of growth. Where do you see kind of the
most significant growth trends when it comes to pharmaceuticals. We've
spent the last what is it, Madison, the last couple
of years talking about the obesity drugs and weight loss drugs,
But where do you see it? We talk often about
genes and genetic and immunotherapy. Where do you see the
(10:45):
real growth coming in the next I don't know, five
to ten years.
Speaker 5 (10:48):
The great question, but it's almost all of the above.
I mean, of course, my check managing what I would
call sant rolo abdominal fat because everybody talks about obesity,
what really matter how much FA do you have in
your abdomenins that surrounds you your liver, your punkreas, your
heart and creates inflammation and insulin resistance and all the consequences.
Speaker 4 (11:09):
We can think about hypertension and others.
Speaker 5 (11:12):
So this is really a big epedemic globally. We need
to address that and that's what companies like lilian Over
are doing today and we are we want to do.
Speaker 4 (11:22):
This with all agents.
Speaker 5 (11:24):
But then you know, we have development in antibody drug conjugates,
We have developments in by specific antibodies for cancer. One
of the most exciting new technology is cell therapy because
cells upy will apply to ematology, cancers, but also potentially
(11:45):
sol tumors and immune diseases. We have no cases, small
numbers early days, but small cases that young women who
suffer from lupus, which is a terrible disease.
Speaker 2 (11:58):
Can be family member who has lucas, it.
Speaker 5 (11:59):
Can be I mean, these patients their life is about
taking drugs. Theories with all the consequences. You can imagine
the organs are destroyed over time by the disease, they
can be cured. You have people with my looma that
can be cured. And so as we progress this technology
and make it more usable, is more easily usable, and
(12:21):
more affordable, it can really transform many fields of medicine,
phrom oncology to iminology.
Speaker 6 (12:30):
I know you've had an amazing tenure at Astra and
there's sort of an obsession in the UK with your
succession plans and what comes next. You know, not to
say that you're leaving anything you don't. We don't want
you to go. What do you want to accomplish before
you and your tenure at Astra.
Speaker 5 (12:48):
Well, one of the things is that I wanted to
do is have a great team, and I have a
great team.
Speaker 4 (12:53):
That's it.
Speaker 5 (12:53):
I have really a fantastic team, and that's why what
you should worry about my succession. We have a great
team and people who can succeed me. So that's I
think one thing, and we need to we constantly try
to improve the team, not only my direct reports, but
they are direct reports and the company as a whole.
Two is the second piece is almost unachievable because science
(13:19):
is never going to be stopping. And the more I progress,
the older it gets, the more science get exciting and
the more excited you. I mean, there's no better time
to be in our industry than there's so much innovation,
so much hope to cure diseases that can't be cured today.
And the last thing was really to finish our site
(13:41):
in Cambridge, because I keep joking internality, I want to
have the two Cambridges, one in Cambridge, you care when
in Cambridge and bos them.
Speaker 4 (13:49):
But that's for the joke.
Speaker 5 (13:50):
But the most exciting really is the science and the
pursuit of new technologies and new products that will make
a difference and change the few Joe medicine. So that's
those other things I want to add, Rice, But I
have to accept that some is going to catch up
with me.
Speaker 2 (14:07):
And unless you create a pill that keeps us going,
I'm kind of giving my fingers crossing exactly glp ones right.
We think it's going to be. You're all, Pascal, we
really enjoyed this. Thank you so much for having me
for all the time. Pascal Sorio. He is astrosenic as
chief executive officer, and of course Bloomberg News his own
health reporter Madison Muller, always a must read on the
Bloomberg and at bloomberg dot com,
Bloomberg Audio Studios, podcasts, radio news.
Speaker 2 (00:08):
Well, as you know, tariff talks continuing, as do presidential
statements about more manufacturing back here in the United States.
The pharmaceutical industry among the latest to be targeted by
President Trump, who made comments Monday from Scotland.
Speaker 3 (00:21):
We'll be announcing on pharmaceuticals sometime in the very near future.
We have a very big plan on pharmaceuticals. We want
to bring a lot of the pharmaceuticals back to America.
Will you know the way they should be. We're going
to want to be making a lot of them ourselves,
all of them in a sense. But you also have
a good pharmaceutical business. We'll be dealing with you on pharmaceuticals.
Speaker 2 (00:43):
All right. That, of course, was President Trump on Monday
from Scotland. We've got a great voice on this and
really the overall pharma industry. Big Pharma. A company that
reported earnings earlier today. We're talking about Astrazenica. Eighty hours
of the company, by the way, are rallying more than
four percent in today's session. Great to have with us
in studio. Pascal Sorio. He is Astrozenica's chief executive officer.
(01:03):
Also with us a member of our editorial team here
at Bloomberg knows this company and industry so well as
Bloomberg News health reporter Madison Muller. Pascal, by the way,
also a former CEO of Genentech. Thank you, thank you
for joining us.
Speaker 4 (01:15):
Welcome, thank you for having me. It's very a pleasure,
thank you.
Speaker 2 (01:18):
It's a pleasure for us. Big space, a space that's
certainly garnered the attention of President Trump. I am curious,
you know, in terms of the President talking about more
manufacturing in the United States, and I know you guys
are making some further investments here, talk to us about
how presidential policy is impacting maybe your business.
Speaker 5 (01:36):
Yeah, I mean, I think, first of all, it's a
great question. But first of all, it's important to really
think about what every country.
Speaker 4 (01:42):
Would want to do. Every country would want.
Speaker 5 (01:45):
To make sure they can and they can secure the
health of their citizens.
Speaker 4 (01:48):
It's a question of national security.
Speaker 5 (01:50):
So nobody should be surprised that the president wants to
reshore manufacturing or pharmaceutical products. I personally, I have seen
this happen since several years, and we decided several years
ago to increase some manufacturing footprint in the US. So
we can actually manufacture many scenes for American patients in America.
(02:11):
Every country would want to do that, and a big
country like America, of course, kind of thought to do it.
Speaker 1 (02:16):
You said that you made that decision several years ago.
How much of the fifty billion dollar pledge was planned
before the President threatened these terraffts.
Speaker 5 (02:24):
Well, we've been pursuing this strategy of manufacturing in China
for China, in the US for the US since five
six years and quite frankly, COVID actually showed us we
were on the right track because we all saw what
happened during COVID, and so we accelrated this movement and
sour fifty billion commitment is a commitment to R and
D but also commitment to manufacturing. We announced together with
(02:46):
the Governor of Virginia, a multi billion dollar investment in
manufacturing in Virginia, and the Governor of Virginia has been
incredibly fast with this team, thirty three days to reach
an agreement. It's incredible, so we're very happy to be there.
We are building a new R and D site in
Kendle Square, Cambridge, Massachusett, with twenty five hundred scientists that
we'll be working there, and there's more to come. We're
(03:08):
just finishing the build of a cels Rup manufacturing site
in Rockville, Maryland. We've expanded in California. So so it's
a sort of multi plane effort across many states across
the US.
Speaker 6 (03:23):
You know, you've said that Virginia obviously has made it
easy to make manufacturing investments there in North Carolina is
pretty similar. Are there other states in the US where
you're having these types of good conversations that are you know,
incentivizing businesses like yours to invest.
Speaker 5 (03:39):
Well, you know, it's hard for me to point the
point that any state that is better than another.
Speaker 4 (03:45):
Let me just say that we have.
Speaker 1 (03:47):
No problem from different in New Jersey.
Speaker 5 (03:55):
Let me let me just say that the company like
ours follow the science. So science is key, and so
you need to be able to recruit the right scientences,
the right engineers. And in Virginia you can do this
because you have some of the best university universities. The
other part is dealing with partners in a public sector
that understand us.
Speaker 4 (04:14):
That we trust each other, we can move fast.
Speaker 5 (04:16):
You know, I always tell people in our company talk
about as Tazenica speed, because there's a lot of competition.
We need to move fast. I've learned Virginia speed. The
governor has moved so quickly. So this is the kind
of thing we want to see, whether it's in America,
in a state or in a country. We want speed
and we want people who understand how we think.
Speaker 1 (04:36):
You want speed. You want people to understand how you
think you want to You said you want to follow
the science. There has been criticism that Robert F. Kennedy, Junior,
the Secretary of Health and Human Services, has not necessarily
always followed the science with his comments when it comes
to medicine, when it comes to drugs, when it comes
to vaccines. How do you look at that and his
role there.
Speaker 5 (04:54):
Well, you know, I'm not here to actually get involved
in political discourses. Let me just say that as a company,
science is at the heart of everything we do. The
reason we have such a large oncology pipeline in particular
and beyond this is because we've focused on science for
the last ten twelve years. And America is where science
(05:17):
in our industry is happening. And that's why it's so
critical to preserve this biosciences leadership. The US has globally
China is also becoming a very big source of innovation
in our industry. Your open fortunately is falling behind for
a variety of reasons. So innovation is happening here. We
need to keep this going.
Speaker 4 (05:36):
We need to.
Speaker 5 (05:36):
Actually continue supporting the leadership. And that's why we invest
fifty billion dollars in this country, not only in manufacturing
but also in R and D.
Speaker 2 (05:45):
What about China, I'd love you to kind of explore
that a little bit. What are you investing in and
building out in China and what might surprise our audience
about the innovation that's happening in China, especially when it
comes to pharmaceuticals.
Speaker 4 (05:58):
Yeah, I think my great question, and I think we
need to start.
Speaker 5 (06:01):
With the the hypothesis, the assumption that basically the more
products or the more innovation exists in the world, the
better it is for everybody, for every patient, because if
you have a patient with cancer, the only thing that
you care about is to be cured if you can
be cured, right, And so innovation in China has really
ramped up very rapidly in the last few years. China
(06:22):
has gone from making generics to me toos to Metwo
plus what we call meet two plus in our industry
to truly innovate these days, innovate in new technologies and
cell therapy in si RN, in many many technologies, and
so China has become the second engine of innovation, not
as big as the US. The US remains the leader
(06:45):
in that field, but China is ramping up very quickly.
Speaker 2 (06:48):
Is the administration with some of it, some would say
questionable disruptive policies. There's been a lot of reporting about
scientists kind of leaving the United States and going elsewhere.
Are you seeing signs of that, whether it's to Europe,
to China to elsewhere because of not supporting, you know,
academia and academic universities. Some of that seems to be
(07:09):
coming back.
Speaker 5 (07:09):
But yeah, but you know, in these things, it's always
difficult to discern what is anecdotal versus what is systemic.
What we have seen in China is really a substantial
return of scientists from the US but also from the
UK and elsewhere, but not because of policy, simply because
they could see opportunities in China. There is money, there
(07:30):
is capital that can be invested. The Chinese are willing
to take rise. The government has facilitated the return of
the scientists, and they've come back. But I can tell
you that a lot of the scientists we work with
and China in about the companies that we partner with,
many of these people are American, the American Chinese. I
mean they go back and forth, back and forth. There
are bridged between the US and China. But they've gone
(07:54):
to China because of the opportunities to create a company,
be funded, tach risk and and.
Speaker 4 (08:00):
Hopefully be successful and buy and large. They've been quite successful.
Speaker 5 (08:05):
I want to say though, that the leadership remains with
the US and we need to maintain this, of course,
I mean the country needs to maintain this.
Speaker 6 (08:14):
There's been some concern though that companies like yours, you know,
not necessarily astro, but big pharmaceutical companies are going to
China for most of their biotech deals. Now, you know,
what would you say to that and what would US
biotech companies need to do to sort of attract investments
from from well, I.
Speaker 5 (08:32):
Mean the first thing I would say is that if
you're a patient, you don't care. What you want is
a drug that will help you. Right, So when we
do a deal with a Chinese company, typically it's because
they've discovered a product and they need help to globalize it.
Because discovering something in a lab is one thing. It
(08:52):
doesn't require a huge amount of money. It require us
very talented people, but the capital requirement is limited. When
you want to develop globally, then you need to scale.
You need billions of dollars of investment in phase two,
phase three, and you need to scale. You need the people,
the expertise. So what we do is we lice on
sindle product and then we develop them globally and then
(09:12):
bring them to patients so they start the innovation started
in China but becomes a global medicine for everybody, so
it really benefits everybody around the world.
Speaker 1 (09:24):
I want to go back to sort of a global
domestic question the idea of your listing, and the Times
of London has said that Astro Zeneka is looking to move.
It's listening to the US.
Speaker 4 (09:35):
Are you going to do that?
Speaker 2 (09:36):
Well, you just shirt with us.
Speaker 3 (09:39):
Yeah.
Speaker 5 (09:40):
We don't comment on rumors, and you know, as a
company over the last ten years we've had so many rumors.
We don't comment on rumors. The only thing I will
say really is the United States is really core to
our company. By two thousand and thirty, we expect fifty
percent of our revenue to come out of the United States.
Today it's forty four forty five percent. We're all tremendously
(10:02):
in the US, and the first half. The US is
the country that innovates, I just audio, but also the
countries that uptake the innovation faster, patients benefit much faster.
So we want to invest here and we want to
grow here, and that is a very critical part of
our company globally.
Speaker 2 (10:22):
Just curious in terms of growth. You know, we've talked
about earnings and your cancer drugs are certainly important in
terms of growth. Where do you see kind of the
most significant growth trends when it comes to pharmaceuticals. We've
spent the last what is it, Madison, the last couple
of years talking about the obesity drugs and weight loss drugs,
But where do you see it? We talk often about
genes and genetic and immunotherapy. Where do you see the
(10:45):
real growth coming in the next I don't know, five
to ten years.
Speaker 5 (10:48):
The great question, but it's almost all of the above.
I mean, of course, my check managing what I would
call sant rolo abdominal fat because everybody talks about obesity,
what really matter how much FA do you have in
your abdomenins that surrounds you your liver, your punkreas, your
heart and creates inflammation and insulin resistance and all the consequences.
Speaker 4 (11:09):
We can think about hypertension and others.
Speaker 5 (11:12):
So this is really a big epedemic globally. We need
to address that and that's what companies like lilian Over
are doing today and we are we want to do.
Speaker 4 (11:22):
This with all agents.
Speaker 5 (11:24):
But then you know, we have development in antibody drug conjugates,
We have developments in by specific antibodies for cancer. One
of the most exciting new technology is cell therapy because
cells upy will apply to ematology, cancers, but also potentially
(11:45):
sol tumors and immune diseases. We have no cases, small
numbers early days, but small cases that young women who
suffer from lupus, which is a terrible disease.
Speaker 2 (11:58):
Can be family member who has lucas, it.
Speaker 5 (11:59):
Can be I mean, these patients their life is about
taking drugs. Theories with all the consequences. You can imagine
the organs are destroyed over time by the disease, they
can be cured. You have people with my looma that
can be cured. And so as we progress this technology
and make it more usable, is more easily usable, and
(12:21):
more affordable, it can really transform many fields of medicine,
phrom oncology to iminology.
Speaker 6 (12:30):
I know you've had an amazing tenure at Astra and
there's sort of an obsession in the UK with your
succession plans and what comes next. You know, not to
say that you're leaving anything you don't. We don't want
you to go. What do you want to accomplish before
you and your tenure at Astra.
Speaker 5 (12:48):
Well, one of the things is that I wanted to
do is have a great team, and I have a
great team.
Speaker 4 (12:53):
That's it.
Speaker 5 (12:53):
I have really a fantastic team, and that's why what
you should worry about my succession. We have a great
team and people who can succeed me. So that's I
think one thing, and we need to we constantly try
to improve the team, not only my direct reports, but
they are direct reports and the company as a whole.
Two is the second piece is almost unachievable because science
(13:19):
is never going to be stopping. And the more I progress,
the older it gets, the more science get exciting and
the more excited you. I mean, there's no better time
to be in our industry than there's so much innovation,
so much hope to cure diseases that can't be cured today.
And the last thing was really to finish our site
(13:41):
in Cambridge, because I keep joking internality, I want to
have the two Cambridges, one in Cambridge, you care when
in Cambridge and bos them.
Speaker 4 (13:49):
But that's for the joke.
Speaker 5 (13:50):
But the most exciting really is the science and the
pursuit of new technologies and new products that will make
a difference and change the few Joe medicine. So that's
those other things I want to add, Rice, But I
have to accept that some is going to catch up
with me.
Speaker 2 (14:07):
And unless you create a pill that keeps us going,
I'm kind of giving my fingers crossing exactly glp ones right.
We think it's going to be. You're all, Pascal, we
really enjoyed this. Thank you so much for having me
for all the time. Pascal Sorio. He is astrosenic as
chief executive officer, and of course Bloomberg News his own
health reporter Madison Muller, always a must read on the
Bloomberg and at bloomberg dot com,
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Special Summer Offer: Exclusively on Apple Podcasts, try our Dateline Premium subscription completely free for one month! With Dateline Premium, you get every episode ad-free plus exclusive bonus content.